1. Singapore Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Prestige BioPharma Limited

Prestige BioPharma Limited

950210.KS
Prestige BioPharma LimitedKR flagKorea Exchange
6,030.00
KRW
-40.00
- -
362.38BMarket Cap
Prestige BioPharma Limited
950210.KS
(Korea Exchange)

Recent

price

6,030.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
2.7
11.49
237.85
267.1
Revenue per Share
-351.6
-143.2
-3,519.2
293.6
-549
370.2
-944.37
Basic EPS, GAAP
-730.41
-650.19
-1,897.65
-2,103.76
-1,267.7
-1,642.12
-1,102.46
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3,068.67
10,968.57
6,991.99
7,420.07
7,263.18
7,418.64
7,444.34
Book Value per Share
1,003.18
9,027.58
6,068.49
7,141
6,366.07
5,227.33
5,662.74
Tangible Book Value per Share
43
52
60
60
60
60
60
Basic Weighted Avg Shares
- -
- -
- -
162
689
14,326
16,047
Sales/Revenue/Turnover
- -
- -
- -
659.44
-9,106.36
-470.14
-520.99
Operating Margin (%)
1,185
1,667
3,867
11,650
16,267
21,801
- -
Depreciation Expense
-14,997
-7,391
-211,450
17,569
-32,921
22,297
-56,737
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
10,855.89
-4,777.6
155.64
-353.56
Profit Margin (%)
41,335
445,890
269,771
176,588
104,494
44,682
-18,673
Working Capital
2,435
3,571
2,656
51,516
40,871
33,139
24,846
LT Debt
137,799
574,961
429,936
546,235
515,502
508,311
554,678
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-2.12
-42.88
4.07
-7.49
5.05
-12.08
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
96,415
57,279
61,097
LT Borrowings
29,988
27,136
24,462
LT Finance Leases
613
497
384
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
791,021
771,413
588,177

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
171,655
120,897
106,460
Cash, Cash Equivalents & STI
134,809
84,964
65,894
Accounts Receivable, Net
422
2,465
495
Inventories
31,448
30,429
35,543
Total Current Liabilities
146,738
117,729
125,133
Payables & Accruals
- -
- -
- -
ST Debt
96,415
57,279
61,097
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
62.41%
-1.39%
Free Cash Flow
- -
49.68%
30.11%
Net Income, GAAP
- -
429.36%
-167.73%
Sales/Revenue/Turnover
- -
- -
1,978.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
67
119
639
-137
689
2025
2,222
3,115
3,340
5,526
14,326
2026
2,308
7,704
509
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-152
-215.8
-23.8
- -
-549
2025
-95.2
-220.4
838.4
- -
370.2
2026
-205
-252.2
-340.8
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
ISR Immune System Regulation Holding AB (publ) (ISR.ST)
Innovent Biologics, Inc. (IVBXF)
Stoke Therapeutics, Inc. (STOK)
Aclaris Therapeutics, Inc. (ACRS)
BioMarin Pharmaceutical Inc. (BMRN)
BioGend Therapeutics Co., Ltd. (6733.TWO)
Business
Prestige BioPharma Limited (950210.KS) develops biosimilars, first-in-class antibody drugs and vaccines for infectious diseases. The Singapore-headquartered biopharmaceutical company, founded in 2015, operates R&D campuses in Singapore and Korea, including the Innovation Discovery Center in Busan and a CDMO facility through Prestige Biologics in Osong, Korea; it targets oncology, autoimmune disorders and unmet needs such as pancreatic cancer across global markets. Core products and pipeline include biosimilars Tuznue (HD201, trastuzumab biosimilar for HER2-positive breast and gastric cancers, Phase III complete), HD204 (bevacizumab biosimilar for solid tumors, Phase III), PBP1502 (adalimumab biosimilar for arthritis, Phase I) and over 12 additional candidates; first-in-class antibodies such as ulenistamab (PBP1510, PAUF-targeted for pancreatic cancer with FDA/EMA Orphan Drug and Fast Track designations, Phase 1/2a ongoing globally); next-generation vaccines including COVID-19 candidates; and diagnostics like the PAUF Pancreatic Cancer Detection Kit. Recent developments encompass European Commission marketing authorization for Tuznue in September 2024, marking the first biosimilar approval for a Singaporean firm in the EU following positive CHMP opinion in July 2024; licensing and supply agreements with Teva for European commercialization in October 2025, Dr. Reddy’s, Tabuk, Cipla and Pharmapark for global markets generating milestone payments, and Biosidus for Latin America in November 2025; opening of the Innovation Drug Center as an R&D hub; and participation in BIO USA 2025 to expand CDMO partnerships.